FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)

BACKGROUND: A targeted agent combined with chemotherapy is the standard treatment in patients with metastatic colorectal cancer (mCRC). The present phase III study was conducted to compare two doses of bevacizumab combined with irinotecan, 5-fluorouracil/leucovorin (FOLFIRI) in the second-line setti...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, S., Takahashi, T., Tamagawa, H., Nakamura, M., Munemoto, Y., Kato, T., Hata, T., Denda, T., Morita, Y., Inukai, M., Kunieda, K., Nagata, N., Kurachi, K., Ina, K., Ooshiro, M., Shimoyama, T., Baba, H., Oba, K., Sakamoto, J., Mishima, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478977/
https://www.ncbi.nlm.nih.gov/pubmed/25908603
http://dx.doi.org/10.1093/annonc/mdv197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478977/
https://www.ncbi.nlm.nih.gov/pubmed/25908603
http://dx.doi.org/10.1093/annonc/mdv197

Ejemplares similares